Visual Impairment Risk After Alcohol Abstinence in Patients With Newly Diagnosed Open-Angle Glaucoma.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 Oct 2023
Historique:
medline: 2 11 2023
pubmed: 19 10 2023
entrez: 19 10 2023
Statut: epublish

Résumé

Recent studies indicate that alcohol consumption is linked to increased intraocular pressure and higher prevalence of open-angle glaucoma (OAG). However, there is insufficient evidence to establish any correlation between alcohol abstinence and improved outcomes in patients with OAG. To evaluate the association between alcohol consumption status (and its changes) and risk of incident severe visual impairment (VI) or blindness in patients with newly diagnosed OAG. This retrospective, nationwide, population-based cohort study used the Korean National Health Insurance Service's claims and health examination database to enroll patients who were newly diagnosed with OAG between January 1, 2010, and December 31, 2011, and had been alcohol drinkers before their OAG diagnosis. The cohort was followed up until December 2020. The data were analyzed from February to December 2022. The patients were categorized into 2 groups based on their post-OAG diagnosis alcohol consumption status: sustainers and abstainers. The risks of severe VI or blindness were compared using weighted Cox proportional hazards regression models along with inverse probability of treatment weighting. Incident severe VI or blindness. Among 13 643 patients with newly diagnosed OAG (mean [SD] age, 53.7 [11.9] years; 12 066 men [88.4%]) who were drinkers, 2866 (21.0%) quit drinking after the diagnosis. During 91 366 person-years of follow-up, patients abstaining from alcohol after their OAG diagnosis had a lower risk of severe VI or blindness than did those who had sustained drinking (adjusted hazard ratio [AHR] after inverse probability of treatment weighting, 0.63; 95% CI, 0.45-0.87). Among the sustained drinkers, both mild consumption (<105 g/wk; AHR, 1.52; 95% CI, 1.01-2.28) and moderate to heavy consumption (≥105 g/wk; AHR, 1.78; 95% CI, 1.11-2.86) after OAG diagnosis were associated with higher risk of severe VI or blindness relative to abstainers. Frequent drinking (≥4 d/wk) also was associated with a higher risk of severe VI or blindness (AHR, 2.56; 95% CI, 1.52-4.33) compared with abstinence. In this cohort study of patients with OAG who were drinkers, abstaining from alcohol after an OAG diagnosis was associated with lower risk of severe VI or blindness. These findings suggest that lifestyle interventions, such as alcohol abstinence, could be essential for patients with newly diagnosed OAG.

Identifiants

pubmed: 37856121
pii: 2810873
doi: 10.1001/jamanetworkopen.2023.38526
pmc: PMC10587786
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2338526

Références

N Engl J Med. 2009 Mar 12;360(11):1113-24
pubmed: 19279343
Clin Ophthalmol. 2013;7:1641-6
pubmed: 23990703
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Front Cell Dev Biol. 2020 Jun 16;8:452
pubmed: 32656207
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Front Cell Neurosci. 2020 Aug 31;14:282
pubmed: 33061892
Clin Kidney J. 2021 Aug 26;15(1):14-20
pubmed: 35035932
Indian J Ophthalmol. 2014 May;62(5):529-37
pubmed: 24881596
Ophthalmology. 2011 Jun;118(6):1024-30
pubmed: 21269703
Ophthalmic Res. 1996;28(3):193-200
pubmed: 8829177
Mol Vis. 2007 Dec 17;13:2282-8
pubmed: 18199969
Jpn J Ophthalmol. 2000 May;44(3):318-9
pubmed: 10913661
Br J Clin Pharmacol. 2012 Mar;73(3):348-62
pubmed: 21988193
PLoS One. 2011 Mar 31;6(3):e18174
pubmed: 21483818
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109130
pubmed: 34773776
Diabetes Metab J. 2020 Oct;44(5):671-678
pubmed: 33115211
Alcohol Res. 2013;35(2):155-73
pubmed: 24881324
Invest Ophthalmol. 1967 Apr;6(2):145-54
pubmed: 6022594
Europace. 2020 Feb 1;22(2):216-224
pubmed: 31620800
Ann Epidemiol. 2007 May;17(5 Suppl):S16-23
pubmed: 17478320
Nat Commun. 2022 Mar 4;13(1):1175
pubmed: 35246521
Mayo Clin Proc. 2014 Mar;89(3):382-93
pubmed: 24582196
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Lancet. 1988 Dec 3;2(8623):1267-73
pubmed: 2904004
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Eur J Public Health. 2021 Feb 1;31(1):105-111
pubmed: 33111144
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Clin Exp Ophthalmol. 2023 May-Jun;51(4):380-394
pubmed: 36859798
Ophthalmology. 2022 Jun;129(6):637-652
pubmed: 35101531
J Addict Dis. 2020 Oct-Dec;38(4):400-410
pubmed: 32580660
Arch Ophthalmol. 2008 Oct;126(10):1421-7
pubmed: 18852421
Ophthalmology. 2021 Jan;128(1):58-69
pubmed: 32730956
Int J Environ Res Public Health. 2018 May 28;15(6):
pubmed: 29843384
Ophthalmol Glaucoma. 2023 Jul-Aug;6(4):366-379
pubmed: 36481453

Auteurs

Yoon Jeong (Y)

Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.

Su Hwan Kim (SH)

Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.

Goneui Kang (G)

Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
EyeLight Data Science Lab, Seoul National University College of Medicine, Seoul, Korea.

Hyung-Jin Yoon (HJ)

Medical Bigdata Research Center, Seoul National University College of Medicine, Seoul, Korea.

Young Kook Kim (YK)

Department of Ophthalmology, Seoul National University Hospital, Seoul, Korea.
EyeLight Data Science Lab, Seoul National University College of Medicine, Seoul, Korea.
Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.

Ahnul Ha (A)

Department of Ophthalmology, Jeju National University Hospital, Jeju-si, Korea.
Department of Ophthalmology, Jeju National University College of Medicine, Jeju-si, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH